cervical cancer
Conditions
Interventions
Case series:apatinib mesylate monotherapy or combined with chemotherapy
Sponsors
Shandong Cancer Hospital and Institute
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years; 2. ECOG(Eastern Cooperative Oncology Group) 0~2; 3. The treatment-naive pathologically confirmed cervical cancer; 4. The subjects received treatment of other damage has been restored (4 edition of the NCI-CTCAE classification is less than or equal to 1 grade), which underwent surgery over 4 weeks; the EGFR TKI class of molecular targeted drugs over 2 weeks; 5. The blood routine and biochemical indexes are in accordance with the following criteria:Hb=80g/L, LANC =1.5 x 10^9/L , PLT=90×10^9/L, ALT and AST<2.5 times of upper limit of normal reference value(Liver metastasis <5×ULN), Bilirubin< 1.5×ULN; SCr (serum creatinine) <1.5 times the upper limit of normal (ULN)or calculated creatinine clearance rate=45 mL/min(Cockcroft-Gault formula); 6. The Expected lifetime =3 months; 7. Participants volunteered to participate in this study, signed informed consent, compliance, with follow-up.
Exclusion criteria
Exclusion criteria: 1. patients who are allergic to lapatinib or any of the ingredients in lapatinib tablets; 2. Patients with uncontrol hypertension in the use of antihypertensive drugs (systolic blood pressure = 140 mmHg or diastolic blood pressure = 90 mmHg); 3. Patients with severe cardiovascular disease: Patients with grade II myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval =470 ms); According to NYHA standard , patients with grade III ~IV cardiac insufficiency left ventricular ejection fraction (LVEF) under 50% confirmed by echocardiography; 4. Patients with positive urinary protein; 5. The following several factors ,such as unable to swallow, chronic diarrhea and intestinal obstruction; 6. Patients with a clear tendency of gastrointestinal bleeding can not be allowed tp into the group, including the following: local active ulceration, fecal, occult blood test(++), The history of hematemesis and melena within 2 months; 7. Cagulation abnormalities. Patients with bleeding tendency, inherited or acquired bleeding tendency and thrombus tendency known to be present; 8. History of abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 month prior to study entry; 9. Accompanied by the central nervous system transfer; 10. Pregnant or lactating women; 11. Patients with a history of psychiatric drug abuse and can not be prevented or have mental disorders; 12. Participated in other drug clinical trials within four weeks; 13. Received VEGFR inhibitor, such as sorafenib sunitinib; 14. According to the researcher's judgment, there is a serious risk of compromising the patient's safety or affecting the patient's completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Safty;OS;DCR;ORR; | — |
Countries
China
Contacts
Public ContactLi Dapeng
Shandong Province Cancer Research Institute
Outcome results
None listed